Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

Share :
Published: 4 Jun 2024
Views: 48
Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Prof Daniel Petrylak speaks to ecancer at ASCO 2024 about a study he presented on the impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.

This analysis evaluates the association between enfortumab vedotin plasma exposure, which is impacted by dose modifications, and safety and efficacy outcomes.

Prof Petrylak reports that enfortumab vedotin improved progression-free survival and overall survival outcomes vs chemotherapy in patients across all exposure quartiles.